503 related articles for article (PubMed ID: 16980981)
1. Virulence factors of Yersinia pestis are overcome by a strong lipopolysaccharide response.
Montminy SW; Khan N; McGrath S; Walkowicz MJ; Sharp F; Conlon JE; Fukase K; Kusumoto S; Sweet C; Miyake K; Akira S; Cotter RJ; Goguen JD; Lien E
Nat Immunol; 2006 Oct; 7(10):1066-73. PubMed ID: 16980981
[TBL] [Abstract][Full Text] [Related]
2. A Yersinia pestis lpxM-mutant live vaccine induces enhanced immunity against bubonic plague in mice and guinea pigs.
Feodorova VA; Pan'kina LN; Savostina EP; Sayapina LV; Motin VL; Dentovskaya SV; Shaikhutdinova RZ; Ivanov SA; Lindner B; Kondakova AN; Bystrova OV; Kocharova NA; Senchenkova SN; Holst O; Pier GB; Knirel YA; Anisimov AP
Vaccine; 2007 Nov; 25(44):7620-8. PubMed ID: 17913308
[TBL] [Abstract][Full Text] [Related]
3. A live attenuated strain of Yersinia pestis KIM as a vaccine against plague.
Sun W; Six D; Kuang X; Roland KL; Raetz CR; Curtiss R
Vaccine; 2011 Apr; 29(16):2986-98. PubMed ID: 21320544
[TBL] [Abstract][Full Text] [Related]
4. Deadly plague versus mild-mannered TLR4.
Dziarski R
Nat Immunol; 2006 Oct; 7(10):1017-9. PubMed ID: 16985495
[No Abstract] [Full Text] [Related]
5. Humanized TLR4/MD-2 mice reveal LPS recognition differentially impacts susceptibility to Yersinia pestis and Salmonella enterica.
Hajjar AM; Ernst RK; Fortuno ES; Brasfield AS; Yam CS; Newlon LA; Kollmann TR; Miller SI; Wilson CB
PLoS Pathog; 2012; 8(10):e1002963. PubMed ID: 23071439
[TBL] [Abstract][Full Text] [Related]
6. Concomitant administration of Yersinia pestis specific monoclonal antibodies with plague vaccine has a detrimental effect on vaccine mediated immunity.
Eyles JE; Butcher WA; Titball RW; Hill J
Vaccine; 2007 Oct; 25(42):7301-6. PubMed ID: 17869388
[TBL] [Abstract][Full Text] [Related]
7. A dam mutant of Yersinia pestis is attenuated and induces protection against plague.
Robinson VL; Oyston PC; Titball RW
FEMS Microbiol Lett; 2005 Nov; 252(2):251-6. PubMed ID: 16188402
[TBL] [Abstract][Full Text] [Related]
8. Deletion of Braun lipoprotein gene (lpp) attenuates Yersinia pestis KIM/D27 strain: role of Lpp in modulating host immune response, NF-kappaB activation and cell death.
Liu T; Agar SL; Sha J; Chopra AK
Microb Pathog; 2010 Jan; 48(1):42-52. PubMed ID: 19737605
[TBL] [Abstract][Full Text] [Related]
9. Identification of New Virulence Factors and Vaccine Candidates for
Andersson JA; Sha J; Erova TE; Fitts EC; Ponnusamy D; Kozlova EV; Kirtley ML; Chopra AK
Front Cell Infect Microbiol; 2017; 7():448. PubMed ID: 29090192
[TBL] [Abstract][Full Text] [Related]
10. Yersinia pestis Yop secretion protein F: purification, characterization, and protective efficacy against bubonic plague.
Swietnicki W; Powell BS; Goodin J
Protein Expr Purif; 2005 Jul; 42(1):166-72. PubMed ID: 15939303
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the lipopolysaccharide of Yersinia pestis.
Prior JL; Hitchen PG; Williamson DE; Reason AJ; Morris HR; Dell A; Wren BW; Titball RW
Microb Pathog; 2001 Feb; 30(2):49-57. PubMed ID: 11162185
[TBL] [Abstract][Full Text] [Related]
12. Neutralization of Yersinia pestis-mediated macrophage cytotoxicity by anti-LcrV antibodies and its correlation with protective immunity in a mouse model of bubonic plague.
Zauberman A; Cohen S; Levy Y; Halperin G; Lazar S; Velan B; Shafferman A; Flashner Y; Mamroud E
Vaccine; 2008 Mar; 26(13):1616-25. PubMed ID: 18304706
[TBL] [Abstract][Full Text] [Related]
13. Effect of deletion of the lpxM gene on virulence and vaccine potential of Yersinia pestis in mice.
Anisimov AP; Shaikhutdinova RZ; Pan'kina LN; Feodorova VA; Savostina EP; Bystrova OV; Lindner B; Mokrievich AN; Bakhteeva IV; Titareva GM; Dentovskaya SV; Kocharova NA; Senchenkova SN; Holst O; Devdariani ZL; Popov YA; Pier GB; Knirel YA
J Med Microbiol; 2007 Apr; 56(Pt 4):443-453. PubMed ID: 17374882
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional profiling of a mice plague model: insights into interaction between Yersinia pestis and its host.
Liu H; Wang H; Qiu J; Wang X; Guo Z; Qiu Y; Zhou D; Han Y; Du Z; Li C; Song Y; Yang R
J Basic Microbiol; 2009 Feb; 49(1):92-9. PubMed ID: 18759226
[TBL] [Abstract][Full Text] [Related]
15. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge.
Palin A; Chattopadhyay A; Park S; Delmas G; Suresh R; Senina S; Perlin DS; Rose JK
Vaccine; 2007 Jan; 25(4):741-50. PubMed ID: 16959385
[TBL] [Abstract][Full Text] [Related]
16. Multiple roles of Myd88 in the immune response to the plague F1-V vaccine and in protection against an aerosol challenge of Yersinia pestis CO92 in mice.
Dankmeyer JL; Fast RL; Cote CK; Worsham PL; Fritz D; Fisher D; Kern SJ; Merkel T; Kirschning CJ; Amemiya K
J Immunol Res; 2014; 2014():341820. PubMed ID: 24995344
[TBL] [Abstract][Full Text] [Related]
17. A Yersinia pestis guaBA mutant is attenuated in virulence and provides protection against plague in a mouse model of infection.
Oyston PC; Mellado-Sanchez G; Pasetti MF; Nataro JP; Titball RW; Atkins HS
Microb Pathog; 2010 May; 48(5):191-5. PubMed ID: 20096773
[TBL] [Abstract][Full Text] [Related]
18. [The effect of Yersinia pestis antigens and strains on the level of lymphocyte blast transformation].
Ledvanov MIu; Emel'ianova NV; Stukova NIu; Shvedun GP; Taranenko TM; Brandzishevskiĭ IuV
Med Parazitol (Mosk); 1998; (4):25-7. PubMed ID: 10050549
[TBL] [Abstract][Full Text] [Related]
19. CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague.
Amemiya K; Meyers JL; Rogers TE; Fast RL; Bassett AD; Worsham PL; Powell BS; Norris SL; Krieg AM; Adamovicz JJ
Vaccine; 2009 Apr; 27(16):2220-9. PubMed ID: 19428836
[TBL] [Abstract][Full Text] [Related]
20. Human cytolytic T cell recognition of Yersinia pestis virulence proteins that target innate immune responses.
Saikh KU; Kissner TL; Dyas B; Tropea JE; Waugh DS; Ulrich RG
J Infect Dis; 2006 Dec; 194(12):1753-60. PubMed ID: 17109349
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
